postsurgical pain control

postsurgical pain control

agents (e.g. acemetacin, diclofenac, flurbiprofen, ibuprofen, ketoprofen, ketoralac) licensed for postoperative pain control; non-steroidal anti-inflammatory drugs alone do not usually achieve adequate postoperative pain control Table 1
Table 1: Principles of pain management
StepPain typeManagement regimeExamples of drug
1Mild to moderateNon-opioid analgesics:
Paracetamol
  • NSAIDs:

  • Pyrazoles


± Adjuvant drugs:
Paracetamol
Aspirin; ibuprofen pheylbutazone; dipyrone
Amitriptyline
Gabapentin
Mexilitine
Ketamine
2Moderate to severeLess potent opioidsCodeine
  • Dihydrocodeine

  • Dextropropoxyphene

± Non-opioid analgesics
± Adjuvant drugs
Paracetamol
As above
3SeverePotent opioidsMorphine
Tramadol
Fentanyl
Oxycodone
± Non-opioid analgesics
± Adjuvant drugs
Paracetamol
As above

Pain management should address both the nociceptive and neuropathic components of pain.

NSAIDs, non-steroidal anti-inflammatory drugs.

References in periodicals archive ?
The Company's flagship product, EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic for postsurgical pain control, was commercially launched in the United States in April 2012.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL([R]) (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012.
EXPAREL addresses an unmet need in postsurgical pain control, which is the need for a longer-lasting, non-opioid analgesic," said David Stack, president and chief executive officer, Pacira Pharmaceuticals, Inc.
Epidural drug delivery is one method of postsurgical pain control recommended by the agency in its practice guidelines.
100 percent of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control at hospital discharge, at 72 hours and on day 10.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL[R] (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and three commercially available products have utilized the Pacira proprietary product delivery technology DepoFoam([R]), a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.